We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-0.47%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.52B
AUM Growth
-$648M
Cap. Flow
+$87.1M
Cap. Flow %
1.58%
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15

Top Buys

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$349M
2
PGNY icon
Progyny
PGNY
+$22.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$19.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$19.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$76.7M
2
PFE icon
Pfizer
PFE
+$59.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$50.3M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$40.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Miscellaneous 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OWLT.WS
151
DELISTED
Owlet, Inc. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
OWLT.WS
– –
-220,704
Closed -$170K
LABP
152
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
– –
-28,322
Closed -$418K
ALBO
153
DELISTED
Albireo Pharma Inc
ALBO
– –
-194,000
Closed -$5.79M
GBT
154
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-50,000
Closed -$1.73M
3 4 5 6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2022 Portfolio in Review

As of Q2 2022, OrbiMed held 158 positions worth $5.52B, down 11% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed's Q2 2022 filing shows 15 new, 26 increased, 36 reduced and 15 closed positions. Its largest new stake was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M. The largest sale was DexCom, an estimated $76.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2022 buy was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M.
  • OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
  • OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
  • OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
  • OrbiMed's ten largest holdings make up 32% of its $5.52B portfolio in Q2 2022.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2022.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.